Xinguang Pharmaceutical Co., Ltd.
新光药业
300519
Shenzhen Stock Exchange
Key Financials
Announcements
Legal Opinion from Shanghai Jintiancheng Law Firm on the 2025 Annual Shareholders' Meeting of New Light Pharmaceutical
Announcement of the Resolutions of the 2025 Annual Shareholders' Meeting
Pre-Disclosure Announcement on the Share Reduction Plan of Shareholders Holding More Than 5% of Shares
Notice of the Company's Annual Shareholders' Meeting in 2025
Announcement on the Reappointment of the Audit Institution for 2026
Pacific Securities Co., Ltd. Regarding the 2025 Fundraising Fund Storage and Usage Verification Opinion of Zhejiang Xinguang Pharmaceutical Co., Ltd.
2025 Independent Director Work Report - Shan Weiguang
2025 Independent Director Work Report - Lv Guiyuan
2025 Independent Director Work Report - Cai Haijing
Announcement of the 2025 Annual Performance Briefing
Tianjian Audit [2026] No. 7017 2025 Internal Control Audit Report
2025 Annual Internal Control Self-Assessment Report
Notice of the 2025 Annual Shareholders' Meeting
2025 Annual Financial Settlement Report
Resolution Announcement of the Eighth Meeting of the Fifth Board of Directors
2025 Annual Board of Directors Work Report
Announcement on the Profit Distribution Plan for 2025
Q1 2026 Report
Special Report on the Storage and Use of Raised Funds for 2025 by Xinguang Pharmaceutical
Verification Report on the Storage and Use of Raised Funds for 2025 (Tianjian Audit [2026] No. 7019)
Report of the Board of Directors Audit Committee on the Evaluation of the Accounting Firm's Performance and Supervision Responsibilities for 2025
Special Audit Explanation on Non-Operating Fund Occupation and Other Related Fund Transactions for 2025 (Tianjian Audit [2026] No. 7018)
Table of Non-Operating Fund Occupation and Other Related Fund Transactions for 2025
Special Opinion of the Board of Directors on the Independence of Independent Directors
2025 Annual Audit Report
2025 Annual Report
Summary of the 2025 Annual Report
Announcement on Continuing to Use Idle Own Funds to Purchase Bank Financial Products
Announcement on the Expiration of the Share Reduction Plan by Shareholders Holding More Than 5% of the Company's Shares
Notes & Comments
Sign in to leave a comment or private note.
Loading…